These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Robinson JG Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323 [TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
6. Statins: potential new indications in inflammatory conditions. Endres M Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422 [TBL] [Abstract][Full Text] [Related]
7. [Do the pleiotropic effects of statins have a clinical significance?]. Vergès B Arch Mal Coeur Vaiss; 2004 Dec; 97(12):1231-5. PubMed ID: 15669365 [TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Marzilli M Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728 [TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein-cholesterol-induced endothelial dysfunction and oxidative stress: the role of statins. Hermida N; Balligand JL Antioxid Redox Signal; 2014 Mar; 20(8):1216-37. PubMed ID: 23924077 [TBL] [Abstract][Full Text] [Related]
11. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
12. Statin therapy-evidence beyond lipid lowering contributing to plaque stability. de Lorenzo F; Feher M; Martin J; Collot-Teixeira S; Dotsenko O; McGregor JL Curr Med Chem; 2006; 13(28):3385-93. PubMed ID: 17168712 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors]. Rosendo AB; Dal-Pizzol F; Fiegenbaum M; Almeida Sd Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):520-5. PubMed ID: 17684611 [TBL] [Abstract][Full Text] [Related]
14. Cardioprotective and other emerging effects of statins. Davignon J Int J Clin Pract Suppl; 2004 Oct; (143):49-57. PubMed ID: 16035396 [TBL] [Abstract][Full Text] [Related]
15. The pleiotropic effects of statins. Calabrò P; Yeh ET Curr Opin Cardiol; 2005 Nov; 20(6):541-6. PubMed ID: 16234628 [TBL] [Abstract][Full Text] [Related]
16. Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Vaughan CJ Am J Cardiol; 2003 Feb; 91(4A):23B-29B. PubMed ID: 12615295 [TBL] [Abstract][Full Text] [Related]
17. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Laufs U Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978 [TBL] [Abstract][Full Text] [Related]
19. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
20. The role of statins in reversing atherosclerosis: what the latest regression studies show. Grines CL J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]